RxDoctor Payments Data

Brian Murray, MD

Urology · Albany, NYNPI 1083659072

Payments from drug & device makers

$129,986in general payments, 2019–2025

Across 699 payments — averaging $185.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • Sumitomo Pharma America, Inc.$24K
  • Bayer$17K
  • Urovant Sciences Inc$17K
  • Astellas Pharma US Inc$9K
  • Boston Scientific$7K
  • plus $11K from 39 others

What the payments were for

  • Consulting fees$10,1218%
  • Speaking & faculty fees$95,92374%
  • Travel & lodging$5,6554%
  • Food & beverage$17,19413%
  • Education$1,0931%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)133$45,378
Sumitomo Pharma America, Inc.70$24,324
Bayer17$17,072
Urovant Sciences Inc25$16,794
Astellas Pharma US Inc56$8,551
Boston Scientific40$7,325
Medline Industries LP1$2,025
Medtronic(2 entities)130$1,351
Caldera Medical, Inc7$1,266
Coloplast15$699
Johnson & Johnson(2 entities)24$553
Teleflex LLC4$545
Axonics, Inc.9$544
Antares Pharma, Inc.28$460
Pfizer27$450
Merck14$312
Myriad Genetic Laboratories, Inc.10$207
Olympus America Inc.7$185
180 Medical, Inc.8$178
Koelis Inc.1$178
Procept Biorobotics Corporation4$157
Tolmar Pharmaceuticals, Inc.9$151
Ferring Pharmaceuticals Inc.6$143
Tolmar, Inc.7$135
Travere Therapeutics, Inc.7$111
Clinical Laserthermia Systems Americas Inc.1$105
C. R. Bard, Inc. & Subsidiaries3$91
Endo Pharmaceuticals Inc.5$84
Novartis3$78
Myovant Sciences Inc.4$71
Neotract Inc.4$60
Endo USA, Inc.2$47
Rochester Medical Corporation3$45
Halozyme Inc2$42
Avadel Specialty Pharmaceuticals, LLC2$38
Laborie Medical Technologies Corp.1$31
Dendreon Pharmaceuticals LLC2$30
Ambu Inc.1$27
Dentsply IH AB1$26
Accord Healthcare, Inc.1$23
Alnylam Pharmaceuticals Inc.1$22
Amgen1$19
Profound Medical Corp.1$18
Hollister Incorporated1$17
Mission Pharmacal Company1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$129,986 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$225,458
Medicare patients
554
Services billed
11,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron214$165,016
MyrbetriqMirabegron72$45,712
Silodosin77$6,591
Estradiol75$4,922
Tamsulosin Hcl174$2,395
Tadalafil31$2,211
Dutasteride110$2,012
NitrofurantoinNitrofurantoin Macrocrystal84$1,778
Potassium Citrate ErPotassium Citrate20$1,582
Oxybutynin Chloride ErOxybutynin Chloride44$1,352
Imipramine Hcl75$1,224
Bicalutamide25$1,063
Trimethoprim22$1,017
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$841
Finasteride59$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$24,324$165,016214 claims
Astellas Pharma US IncMyrbetriq$8,551$45,71272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →